• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Substance Use Disorders Are Under-Recognized in Patients With Diabetes

Substance Use Disorders Are Under-Recognized in Patients With Diabetes

July 1, 2018
Rehan Aziz, MD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Rehan Aziz, MD Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Wu LT et al, Drug and Alcohol Dep 2018;186:86–93

Type 2 diabetes (T2D) is a common condition with high treatment costs and significant morbidity and mortality. In 2015, an estimated 30.2 million American adults had T2D. Diabetes can be comorbid with other behavioral health disorders (BHDs), and this can lead to additional costs and increased morbidity and mortality risk.

Both T2D and BHDs are linked to more emergency department visits and hospital readmissions, and they are in the top diagnoses for adults who are “super-utilizers” of hospital care. However, comorbid BHD and T2D, especially with substance use disorders (SUDs), remain under-recognized and undertreated.

This study used a risk algorithm developed from Duke University Health System electronic health records to identify high-risk patients and examine the prevalence and correlates of BHDs in T2D. Risk scores were based on serious outcomes, such as hospital/ED admission or death. The final analysis included 263 adults with T2D seen at Duke from 2012 to 2016. The sample mean age was 54.6 years, and 54% were women.

Almost half (48%) of patients with T2D also had a SUD, and 75% also had BHDs. Overall, 82% of the sample had a SUD or BHD, with 41% having both.

In the SUD group, 13% were ­related to alcohol, 39% were due to tobacco, and 23% were due to any drug. In the BHD group, 53% were related to mood disorders, 37% to sleep, 33% to anxiety, 15% to schizophrenia/psychosis/delusion, 14% to dementia/delirium/amnestic/cognitive impairment, and 9% to adjustment.

Greater odds of a comorbid SUD were noted among men and those who were never married. Women had higher odds of mood (2.5) and anxiety disorders (5.5). Having a diagnosis of SUD/BHD was positively associated with greater numbers of ED/inpatient encounters, with ratios ranging from 2.1 for sleep disorders to 6.7 for the presence of ≥ 2 SUDs.

CATR’s Take
This study provides evidence that there is a high rate of SUD/BHD comorbid with T2D. These comorbidities can compromise treatment adherence, exacerbate medical complications, and increase health care utilization and costs. Hopefully, this report will help inform screening and multidisciplinary care coordination efforts for this population.
Addiction Treatment
KEYWORDS research-update
    Rehan Aziz, MD

    Breaking the Silence: Addressing the Hidden Crisis of Elder Abuse

    More from this author
    www.thecarlatreport.com
    Issue Date: July 1, 2018
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Adolescent Addiction, CATR July/August 2018
    Adolescents With ADHD and Substance Use Disorders: A Primer
    Talking to Parents and Adolescent Patients About Substance Use
    Can Computerized Interventions Reduce Cannabis Use?
    Substance Use Disorders Are Under-Recognized in Patients With Diabetes
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.